Home » Trials » SLCTR/2017/028


Effectiveness of Vitamin C in reducing morbidity in patients with Dengue fever - A double blinded randomized placebo controlled pilot study. -

SLCTR Registration Number

SLCTR/2017/028


Date of Registration

30 Aug 2017

The date of last modification

Sep 27, 2017



Application Summary


Scientific Title of Trial

Effectiveness of Vitamin C in reducing morbidity in patients with Dengue fever - A double blinded randomized placebo controlled pilot study.


Public Title of Trial

Effectiveness of Vitamin C in reducing morbidity in patients with Dengue fever - A double blinded randomized placebo controlled pilot study.


Disease of Health Condition(s) Studied

Dengue fever


Scientific Acronym

VITCDEN (vitamin C in Dengue infection)


Public Acronym

VITCDEN (vitamin C in Dengue infection)


Brief title

Vitamin C in dengue fever


Universal Trail Number

U1111-1199-3246


Any other number(s) assigned to the trial and issuing authority

03.05.2017:4.4 (ERC, Ruhuna)


Trial Details


What is the research question being addressed?

Is Vitamin C effective in reducing morbidity in patients with Dengue fever?


Type of study

Interventional


Study design

Allocation

Randomized controlled trial


Masking

Double blinded


Control

Placebo


Assignment

Parallel


Purpose

Treatment


Intervention(s) planned

The study will be carried out in the medical wards of the Teaching Hospital, Karapitiya, Sri Lanka. Patients will be randomized using simple randomization.

Those in the treatment arm would receive oral liposomal vitamin C 1000mg bid (twice daily) for 5 days and the control arm would receive a matching placebo for the same duration.

Following investigations will be done in both arms, full blood count (twice daily) Liver enzymes (daily) CRP (at least twice during hospital stay) Dengue serotypes Dengue IgG, IgM antibodies at day 5 or 6 TNF (once during the hospital stay) IL-6 (once during the hospital stay) Ultrasound scan (daily- to look for any evidence of leakage).

Both arms will receive standard care which will include observation, symptomatic treatment including paracetamol for fever and domperidone for vomiting and management of complications of dengue infection (i.e. iv fluid bolus, dextran or blood transfusion depending on the type of complication).

Participants, health care providers, data collectors, outcome adjudicators, data analysts will be blinded to the therapy received.


Inclusion criteria

  1. Male and female patients aged 12-70 years.
  2. Previously healthy patients coming with dengue fever
  3. Within the first 3 days of fever
  4. Positive NS1 dengue antigen
  5. Platelet count more than 100 000/mm3

Exclusion criteria

  1. Patients under age of 12 years and above 70 years
  2. Those who have any evidence of plasma leakage, shock or impeding shock, fluid overload, internal bleeding at that time of recruitment
  3. Those who have severe vomiting or inability to take oral fluids
  4. Drowsy patients - Drowsiness will be assessed clinically based on appearance followed by glasgow coma scale.
  5. Those who have liver failure with clinical or biochemical evidence
  6. Those who have AST or ALT more than 100 IU/L on admission
  7. Patients with other co-morbidities such as diabetes mellitus, hypertension, ischemic heart disease, bronchial asthma, thyroid disorders etc.
  8. Patients who are on other medication (statins, metformin, beta blockers)
  9. Patients who are severely dehydrated
  10. Patients who get admitted later (more than 3 days after onset of fever)
  11. Patients who are extremely obese,- BMI more than 27 kg/m2
  12. Patients with known fatty liver disease
  13. Patients who have used any alternative medicine eg:- indigenous medicine
  14. Patients with diagnosed mental illness
  15. Patients with ongoing other infections, malignancy


Primary outcome(s)

  1. Number of days need to be hospitalised.
  2. Number of patients going into leaking phase
  3. Secondary bacterial infection

Primary outcome(s) - Time of assessment(s)

  1. Daily during hospital stay
  2. Daily during hospital stay
  3. Daily during hospital stay

Secondary outcome

None


Secondary outcome(s) - Time of assessment(s)

None



Target number/sample size

60 (30 in each arm)


Countries of recruitment

Sri Lanka


Anticipated start date

2017-09-01


Anticipated end date

2017-11-30


Recruitment status

Recruiting


State of ethics review approval

Approved by the Ethics Review Committee, Faculty of Medicine, University of Ruhuna on 14.06.2017 (Ref: 03.05.2017:4.4)


Funding source

LivOn Labs, USA



Contact & Sponsor Information


Contact person for Scientific Queries/Principal Investigator

Dr. H M M Herath
Senior Lecturer in Clinical Medicine, Consultant Physician
Faculty of Medicine, University of Ruhuna, Galle, Sri Lanka
Tel: +94912234803
Mob: 0773453217

herathtp@gmail.com

Contact Person for Public Queries

Dr. H M M Herath
Senior Lecturer in Clinical Medicine, Consultant Physician
Faculty of Medicine, University of Ruhuna, Galle, Sri Lanka
Tel: +94912234803
Mob: 0773453217

herathtp@gmail.com


Primary study sponsor/organization

Jonathan Orchard BSc(Hons) MBAcC
Director- LivOn Labs
2654W Horizon Ridge Pkwy B5- 108, Henderson, NV 89052, USA
+1 (702) 9365910 +447786233317

jonathan@abundanceandhealth.co.uk

Secondary study sponsor (If any)

None